OBJECTIVES: Persons from sub-Saharan Africa (SSA) are increasingly enrolled in the Swiss HIV Cohort Study (SHCS). Cohorts from other European countries showed higher rates of viral failure among their SSA participants. We analyzed long-term outcomes of SSA versus North Western European participants. DESIGN: We analyzed data of the SHCS, a nation-wide prospective cohort study of HIV-infected adults at 7 sites in Switzerland. METHODS: SSA and North Western European participants were included if their first treatment combination consisted of at least 3 antiretroviral drugs (cART), if they had at least 1 follow-up visit, did not report active injecting drug use, and did not start cART with CD4 counts >200 cells per microliter during pregnancy. Early viral response, CD4 cell recovery, viral failure, adherence, discontinuation from SHCS, new AIDS-defining events, and survival were analyzed using linear regression and Cox proportional hazard models. RESULTS: The proportion of participants from SSA within the SHCS increased from 2.6% (<1995) to 20.8% (2005-2009). Of 4656 included participants, 808 (17.4%) were from SSA. Early viral response (6 months) and rate of viral failure in an intent-to-stay-on-cART approach were similar. However, SSA participants had a higher risk of viral failure on cART (adjusted hazard ratio: 2.03, 95% confidence interval: 1.50 to 2.75). Self-reported adherence was inferior for SSA. There was no increase of AIDS-defining events or mortality in SSA participants. CONCLUSIONS: Increased attention must be given to factors negatively influencing adherence to cART in participants from SSA to guarantee equal longer-term results on cART.
OBJECTIVES:Persons from sub-Saharan Africa (SSA) are increasingly enrolled in the Swiss HIV Cohort Study (SHCS). Cohorts from other European countries showed higher rates of viral failure among their SSA participants. We analyzed long-term outcomes of SSA versus North Western European participants. DESIGN: We analyzed data of the SHCS, a nation-wide prospective cohort study of HIV-infected adults at 7 sites in Switzerland. METHODS: SSA and North Western European participants were included if their first treatment combination consisted of at least 3 antiretroviral drugs (cART), if they had at least 1 follow-up visit, did not report active injecting drug use, and did not start cART with CD4 counts >200 cells per microliter during pregnancy. Early viral response, CD4 cell recovery, viral failure, adherence, discontinuation from SHCS, new AIDS-defining events, and survival were analyzed using linear regression and Cox proportional hazard models. RESULTS: The proportion of participants from SSA within the SHCS increased from 2.6% (<1995) to 20.8% (2005-2009). Of 4656 included participants, 808 (17.4%) were from SSA. Early viral response (6 months) and rate of viral failure in an intent-to-stay-on-cART approach were similar. However, SSA participants had a higher risk of viral failure on cART (adjusted hazard ratio: 2.03, 95% confidence interval: 1.50 to 2.75). Self-reported adherence was inferior for SSA. There was no increase of AIDS-defining events or mortality in SSA participants. CONCLUSIONS: Increased attention must be given to factors negatively influencing adherence to cART in participants from SSA to guarantee equal longer-term results on cART.
Authors: Gelane Workneh; Leah Scherzer; Brianna Kirk; Heather R Draper; Gabriel Anabwani; R Sebastian Wanless; Haruna Jibril; Neo Gaetsewe; Boitumelo Thuto; Michael A Tolle Journal: AIDS Care Date: 2012-04-26
Authors: Alexandra U Scherrer; Bruno Ledergerber; Viktor von Wyl; Jürg Böni; Sabine Yerly; Thomas Klimkait; Cristina Cellerai; Hansjakob Furrer; Alexandra Calmy; Matthias Cavassini; Luigia Elzi; Pietro L Vernazza; Enos Bernasconi; Huldrych F Günthard Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240
Authors: Anne Guionnet; Bárbara Navaza; Belén Pizarro de la Fuente; María Jesús Pérez-Elías; Fernando Dronda; Rogelio López-Vélez; José A Pérez-Molina Journal: BMC Public Health Date: 2014-10-29 Impact factor: 3.295
Authors: Sabrina K Been; David A M C van de Vijver; Pythia T Nieuwkerk; Inês Brito; Sarah E Stutterheim; Arjan E R Bos; Mireille E G Wolfers; Katalin Pogány; Annelies Verbon Journal: PLoS One Date: 2016-10-05 Impact factor: 3.240
Authors: Sara Lodi; Huldrych F Günthard; David Dunn; Federico Garcia; Roger Logan; Sophie Jose; Heiner C Bucher; Alexandra U Scherrer; Marie-Paule Schneider; Matthias Egger; Tracy R Glass; Peter Reiss; Ard van Sighem; T Sonia Boender; Andrew N Phillips; Kholoud Porter; David Hawkins; Santiago Moreno; Susana Monge; Dimitrios Paraskevis; Metallidis Simeon; Georgia Vourli; Caroline Sabin; Miguel A Hernán Journal: AIDS Date: 2018-01-28 Impact factor: 4.177